Bret Weinstein on money: what the evidence says · JRE #2198

FACT CHECK // JRE #2198 // EXHIBIT LOG
EPISODE AIRED SEP 4, 2024 · THE JOE ROGAN EXPERIENCE
CLAIM CMTLWNL9STATUS: PUBLISHED
SUBJECT: MONEY
Timestamp2:04:54
Aired
// 00 · ABSTRACT

The short answer

Weinstein and Rogan state that Pfizer and Moderna together generated over $100 billion in COVID vaccine revenue between 2021 and 2022. Pfizer's own SEC-filed full-year 2022 earnings release reports Comirnaty direct sales and alliance revenues of $36.78 billion in 2021 and $37.81 billion in 2022, a two-year total of about $74.6 billion, close to the $75 billion figure cited.

RulingNeeds Context

Not a true/false call. Every claim is logged with its sources; read the exhibits below.

// THE CLAIM · ON TAPE
Cominardi says generated 75 billion between 21 and 22 doesn't include 23 and then 36 billion for spike, which I think is... Is that Moderna? Yeah. So, over $100 billion.
Bret Weinstein@ 2:04:54
Watch on YouTubeJUMP TO 2:04:54

What the evidence says 01 / RECORD

The claim states that Pfizer's COVID-19 vaccine (Comirnaty) generated about $75 billion and Moderna's COVID-19 vaccine (Spikevax) generated about $36 billion between 2021 and 2022, for a combined total exceeding $100 billion. Pfizer's own SEC-filed full-year 2022 earnings release reports Comirnaty direct sales and alliance revenues of $36.78 billion in 2021 and $37.81 billion in 2022, a two-year total of about $74.6 billion, close to the $75 billion figure cited. Moderna, whose only commercialized product in this period was its COVID-19 vaccine, reported total product sales of $17.68 billion in 2021 and $18.44 billion in 2022 per its SEC-filed fourth-quarter and full-year 2022 results, a two-year total of about $36.1 billion, matching the $36 billion figure cited. Summing both companies' reported figures yields approximately $110.7 billion in combined COVID-19 vaccine revenue for 2021-2022, consistent with the claim that the combined total exceeded $100 billion. The specific dollar figures and the overall conclusion align closely with the companies' own regulatory financial disclosures.

/// factcheckjoerogan.com